Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168320 | 0.84 | TGFBR1 (0.44) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6169745 | 0.83 | TGFBR1 (0.43) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL2615988 | 0.81 | RAB9A (0.56) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6168797 | 0.79 | TGFBR1 (0.41) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL30387367 | 0.79 | TGFBR1 (0.74) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6759987 | 0.79 | TGFBR1 (0.74) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6167362 | 0.78 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6169733 | 0.78 | PDE3B (0.48) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6168732 | 0.78 | KMT2A (0.51) | RAB9AMAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL6169245 | 0.76 | PDE3B (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | claimed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | claimed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | claimed |
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | claimed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | claimed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885RIPK2 2560/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885RIPK2 2560/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885RIPK2 2560/4885 |
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885MAPK14 2320/4885RIPK2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.